Archer Aviation Inc vs Novo Nordisk A/S — how do they compare? Archer Aviation Inc trades at $6.29 (market cap $5.23B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 39.7× Archer Aviation Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | NVO | |
|---|---|---|
Market Cap | $5.23B | $207.85B |
Sector | Industrials | Health |
52-Week High | $13.64 | $63.98 |
52-Week Low | $4.44 | $35.29 |
Enterprise Value | $3.79B | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.29, up 0.48% with strong technical momentum and bullish analyst sentiment. The company reported Q2 2026 revenue of $5 million, beating expectations by 150%, while announcing a transformative Boeing deal acquiring three businesses for a 20% equity stake. Despite negative profitability metrics and substantial cash burn, the strategic expansion into defense and autonomous aviation technology has driven recent stock appreciation.
The outlook remains speculative with significant execution risks, but strategic partnerships and regulatory progress provide potential upside. Investors face dilution concerns from the $750 million equity offering while betting on long-term commercialization of air taxi technology. The stock's valuation appears stretched with P/S ratio of 719.85, requiring successful commercialization to justify current levels.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →